EKF Diagnostics Holdings PLC Strategic Update (3163D)
24 10월 2015 - 1:06AM
UK Regulatory
TIDMEKF
RNS Number : 3163D
EKF Diagnostics Holdings PLC
23 October 2015
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Strategic Update
The Board note the announcement by Jinjing (Group) Co., Ltd.
that they do not intend to make an offer for the Company. The
Company is no longer in an offer period under the City Code and,
accordingly, the requirement to make disclosures under Rule 8 of
the City Code has now ceased.
As outlined in the Company's conclusion of strategic review
announcement of 18 August 2015, as the interest shown in the
Company has not led to a realisation event, the Board now intend to
invite Mr Ron Zwanziger to become Chairman, with the current
Chairman becoming deputy Non-Executive Chairman.
Ron Zwanziger has been the founder and Chief Executive Officer
of three highly successful medical diagnostic companies. Mr
Zwanziger was Chairman, Chief Executive Officer and President of
Alere Inc. from its inception in May 2001 until July 2014. Alere is
a global diagnostics company with a $4 billion market
capitalisation listed on the New York Stock Exchange. Prior to
Alere Mr Zwanziger served as Chairman, Chief Executive Officer and
President of Inverness Medical Technology, from its inception in
1992 to November 2001, when that company was acquired by Johnson
& Johnson. From 1981 to 1991, he was Chairman and Chief
Executive Officer of MediSense, a medical device company. Mr
Zwanziger served as a director of AMAG Pharmaceuticals, Inc. from
November 2006 to December 2011. Finally, Mr Zwanziger is currently
Chairman and Chief Executive Officer of Lumira Holdings Ltd.
The Company announced on 24 August 2015 that it had received a
non-binding preliminary proposal from an unrelated third party of
US$115 million to $125 million for the Company's Point-of-Care
business (which excludes the Clinical Chemistry and Molecular
Diagnostics businesses). This non-binding preliminary proposal has
now been withdrawn.
David Evans, Chairman of EKF commented:
"Although we had a number of expressions of interest this has
not let to a realisation event. We now look forward to working with
Mr Zwanziger as Chairman to build on the solid foundations of the
EKF business. Mr Zwanziger brings strategic vision, leadership,
extensive business and operating experience and an immense
knowledge of the industry to our Board."
Further disclosure in accordance with Schedule Two paragraph (g)
of the AIM Rules will be made in due course.
EKF Diagnostics Holdings plc Tel: 029 2071 0570
David Evans, Executive Chairman Mob: 07740 084 452
Julian Baines, CEO Mob: 07788 420 859
Paul Foulger, CFO Mob: 07710 989 255
Panmure Gordon (UK) Limited Tel: 020 7886 2500
Robert Naylor (Corporate Finance)
Paul Fincham (Corporate Finance)
Karri Vuori (Corporate Finance)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLBDGSGDBGUX
(END) Dow Jones Newswires
October 23, 2015 12:06 ET (16:06 GMT)
International Brand Licensing (LSE:IBL)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
International Brand Licensing (LSE:IBL)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
